Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Things appear to be proceeding to plan at Hikma Pharmaceuticals as it has reiterated its revenue growth guidance for 2012, despite a few setbacks in its generic drugs business. "We are making good progress towards delivering our targets for this year and surpassing the important milestone of $1bn i
Read more- Chicago PMI, US consumer spending disappoints - Spain joins the UK in recession - Global stock markets in the red With economic data missing expectations Stateside and Spain continuing to dampen the outlook for the Eurozone economy, London's FTSE 100 index slumped on Monday, snapping a four-day w
Read moreEssar Energy saw its share price jump by nearly a tenth today with analysts pinning the stock's performance to a simple correction following its recent slump. Even after taking today's rise into account, the stock is still worth less than half off its six-month high of 312.1p. Platinum producer Aqu
Read moreAnglo American: AlphaValue downgrades from neutral to reduce, target cut from 7,115p to 6,970p. AstraZeneca: Jefferies upgrades from hold to buy, target cut from 3,050p to 2,975p; JP Morgan Cazenove upgrades from underweight to neutral, target hiked from 2,800p to 3,050p. British Sky Broadcasting:
Read moreMerchant Securities has cut its rating for luxury brand Burberry from buy to hold on valuation grounds, but has maintained its positive stance on the group. "We continue to believe that Burberry is a beneficiary of growing demand from global luxury travellers, especially in Asia, Middle East and Ru
Read moreUBS has upgraded its rating for pharmaceuticals group Hikma from neutral to buy, leaving its 755p target price unchanged, following the sell-off since the firm's full-year results last month. The broker sees a 10% and 6% downside risk to 2012 and 2013 earnings per share estimates - "we believe cons
Read moreBHP Billiton: Jefferies reiterates buy rating and 2,500p target. Burberry: Merchant Securities downgrades from buy to hold; Investec maintains buy recommendation and 1,690p target. Dairy Crest: Numis upgrades from add to buy. Daily Mail & General Trust: Investec maintains buy rating and 578p targ
Read more4imprint: Peel Hunt keeps buy rating and 345p target. Aegis: Nomura reiterates buy rating and 210p target; HB Markets upgrades from sell to hold. Antofagasta: Jefferies keeps hold and 1,214p target. Bunzl: Goldman Sachs downgrades from neutral to sell, target lifted from 940p to 988p. Diageo: Je
Read moreDrugs developer Hikma Pharmaceuticals kept up its track record of doubling revenues every four years, but it will be less pleased with the slide in profits in 2011 as exceptional charges increased. Profits before tax fell from $120.98m to $93.89m, after operating expenses soared. Group operating ex
Read moreBarclays: Goldman Sachs cuts to sell from neutral. BG Group: Evolution Securities keeps buy recommendation and 1,800p target. BG Group: Nomura maintains buy and 1,750p target. ITV: Peel Hunt retains buy and 73p target. ITV: Investec maintains hold rating and 55p target. Cairn Energy: UBS cuts
Read moreTwo non-executive directors at Hikma Pharmaceuticals have upped their stakes in the Arab world-focused pharmaceutical company. Ronald Goode took 8,000 shares at 633p a time, lifting his stake to 22,700 shares, while Robert Pickering snapped up 7,500 shares at 617p a pop, having previously had none.
Read moreCarillion, which bought Eaga, the home insulation and green energy business, in the spring, has now raised its estimate for annualised cost savings from £9 million to £15 million, notes the Tempus column in the Times. Carillion, like its rival support services group Kier, is now seeing the promised,
Read moreUBS says that Tullow Oil is in a comfortable financial position, and with catalysts "plentiful" in September, the broker keeps its buy rating on the Africa-focused oil giant. "With the expectation of receiving $2.9bn cash for the sale of its Ugandan assets, coupled with growing cashflows from Jubil
Read moreUBS has cut its target price for FTSE 250 pharmaceuticals firm Hikma from 900p to 850p after first half revenues and earnings came in below forecasts. The broker notes that revenues in the six months to 30 June of $395m missed its forecasts by 1.7% and consensus estimates by 0.4%. "While reported
Read moreDisruption in Libya and Yemen contributed to a fall in profits at pharmaceuticals group Hikma in the half year to 30 June. Gross profit fell to $172.6m from $178.5m over the same period the previous year, on revenues that climbed to $394.8m from $377.7m. Gross profits in the company's branded prod
Read more
Last checked at